azelastine and maprotiline interaction

azelastine and maprotiline both increase sedation. Potential for interaction, monitor

azelastine and lurasidone interaction

lurasidone, azelastine. Either increases toxicity of the other by Other  

 Significant interaction possible, monitor closely 

 Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity

azelastine and loxapine interaction

azelastine and loxapine both increase sedation. Potential for interaction, monitor

azelastine and lormetazepam interaction

azelastine and lormetazepam both increase sedation. Potential for interaction, monitor

azelastine and lorazepam interaction

azelastine and lorazepam both increase sedation. Potential for interaction, monitor

azelastine and loprazolam interaction

azelastine and loprazolam both increase sedation. Potential for interaction, monitor

azelastine and lomitapide interaction

azelastine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Significant interaction possible, monitor closely. Lomitapide dose should not exceed 30 mg/day

azelastine and lofexidine interaction

azelastine and lofexidine both increase sedation. Potential for interaction, monitor

azelastine and lofepramine interaction

azelastine and lofepramine both increase sedation. Potential for interaction, monitor

azelastine and lisdexamfetamine interaction

azelastine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor

azelastine and levorphanol interaction

azelastine and levorphanol both increase sedation. Potential for interaction, monitor

azelastine and levalbuterol interaction

azelastine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor

azelastine and kava interaction

kava increases effects of azelastine by pharmacodynamic synergism. Significant interaction possible, monitor closely. May enhance CNS depression

azelastine and ivacaftor interaction

azelastine increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for interaction, monitor. Monitor when coadministered with weak CYP3A4 inhibitors

azelastine and isoproterenol interaction

azelastine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Potential for interaction, monitor

azelastine and imipramine interaction

azelastine and imipramine both increase sedation. Potential for interaction, monitor

azelastine and iloperidone interaction

azelastine and iloperidone both increase sedation. Potential for interaction, monitor

azelastine and hydroxyzine interaction

azelastine and hydroxyzine both increase sedation. Potential for interaction, monitor

azelastine and hydromorphone interaction

azelastine and hydromorphone both increase sedation. Potential for interaction, monitor

azelastine and hydrocodone interaction

azelastine and hydrocodone both increase sedation. Potential for interaction, monitor